Home > Boards > US Listed > Biotechs >

Bristol Myers Squibb (BMY)

BMY RSS Feed
Add BMY Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 11/16/2020 5:35:22 PM - Followers: 35 - Board type: Free - Posts Today: 0
BMY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BMY News: Statement of Changes in Beneficial Ownership (4) 11/30/2020 05:52:59 PM
BMY News: Statement of Changes in Beneficial Ownership (4) 11/25/2020 04:33:11 PM
BMY News: Statement of Changes in Beneficial Ownership (4) 11/25/2020 04:32:58 PM
BMY News: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable A... 11/24/2020 06:59:00 AM
BMY News: Statement of Changes in Beneficial Ownership (4) 11/23/2020 05:41:04 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 11/30/2020 05:52:59 PM
PostSubject
#962  Sticky Note BMY 3Q20 results—raises_2020_EPS guidance: DewDiligence 11/05/20 08:11:59 AM
#968   FDA_unable_to_meet_BMY’s_liso-cell_PDUFA_date—(today)—due_to_COVID: https://f DewDiligence 11/16/20 05:35:22 PM
#967   BMY sells $7B of 3-30yr notes—to fund MYOK acquisition: DewDiligence 11/10/20 09:08:21 AM
#966   Keytruda+Yervoy_not_better_than_Keytruda_monotherapy_in_1L-NSCLC with PD-L1>=50% DewDiligence 11/09/20 06:46:36 PM
#965   Phase-2 Deucravacitinib data in PA: DewDiligence 11/09/20 08:48:33 AM
#964   Pulling out all the right stops as it Seeker213 11/06/20 05:21:32 AM
#963   BMY 3Q20 CC slides: DewDiligence 11/05/20 08:35:02 AM
#962   BMY 3Q20 results—raises_2020_EPS guidance: DewDiligence 11/05/20 08:11:59 AM
#961   BMY’s Deucravacitinib bests AMGN’s Otezla_in_phase-3_psoriasis_study: DewDiligence 11/03/20 08:54:33 AM
#960   https://www.businesswire.com/news/home/20201028005276/en/insitro-Announces-Five- DewDiligence 10/28/20 07:09:10 AM
#959   Opdivo/Cabometyx BLA/NDA for RCC combination therapy has 2/21/21 DewDiligence 10/19/20 10:03:16 AM
#958   Just In: $BMY Why I Think Bristol Myers whytestocks 10/17/20 08:00:30 AM
#957   BMY reports full dataset for Zeposia phase-3 in UC: DewDiligence 10/12/20 10:52:37 AM
#956   BMY’s enterprise value increased by ~$6B today, which DewDiligence 10/07/20 07:35:59 PM
#955   Opdivo/chemo shows statsig-superior pCR compared to chemo alone DewDiligence 10/07/20 02:17:37 PM
#954   BMY acquires MYOK for $13.1B in cash: DewDiligence 10/05/20 09:32:07 AM
#953   Yervoy/Opdivo doesn’t show statsig RFS benefit in adjuvant DewDiligence 10/02/20 05:20:17 PM
#952   FDA approves Opdivo/Yervoy for mesothelioma: DewDiligence 10/02/20 04:24:24 PM
#951   Opdivo monotherapy—>statsig-superior DFS—against placebo—in adjuvant UC: DewDiligence 09/24/20 05:07:16 PM
#950   ... BAD NEWS $BMY CAPITULATION COMING ... Going below @LaughinPaulRyan 09/23/20 01:35:55 PM
#949   CHMP approves Opdivo/Yervoy in 1L-NSCLC based on CHECKMATE-9LA study: DewDiligence 09/18/20 10:43:42 AM
#948   BMY settles Revlimid US-patent litigation with RDY: DewDiligence 09/17/20 09:46:41 AM
#947   FDA approves Onureg (azacitadine) as maintenance therapy for DewDiligence 09/01/20 03:25:43 PM
#946   Article mentioning BMS today Nfixus 08/31/20 03:55:15 PM
#945   BMY licenses Dragonfly’s IL-12 program: DewDiligence 08/17/20 10:31:08 AM
#944   Opdivo monotherapy shows statsig DFS benefit vs placebo DewDiligence 08/11/20 11:21:46 AM
#943   Opdivo/chemo shows statsig OS/PFS benefit vs chemo alone DewDiligence 08/11/20 11:16:33 AM
#942   $BMY / Potential Breakout Target for #BristolMyers TFMG 08/10/20 06:29:49 PM
#941   Opdivo+Yervoy bests chemo in 1L-mesothelioma—OS HR=0.74: DewDiligence 08/08/20 01:01:31 PM
#940   BMY reports 2Q20 results—raises full-year EPS guidance slightly: DewDiligence 08/06/20 08:18:58 AM
#939   BMY/PFE win Eliquis patent case: DewDiligence 08/05/20 05:53:20 PM
#938   BMY/BLUE resubmit bb2121 BLA following May 2020 RTF: DewDiligence 07/29/20 04:57:44 PM
#937   News: $BMY If You Invested $1,000 in Bristol whytestocks 07/19/20 07:45:51 AM
#936   BMY slides from today’s webcast on immunology/cardiology: DewDiligence 06/26/20 11:29:56 AM
#935   Are we eyeing ONTX? doczaius 06/25/20 07:29:56 PM
#934   BMY slides from today’s webcast on hematology; DewDiligence 06/25/20 12:54:06 PM
#933   BMY slides from today’s webcast on early-stage pipeline DewDiligence 06/22/20 12:36:40 PM
#932   BMY director bought $0.5M of stock on open DewDiligence 06/16/20 05:43:43 PM
#931   I’m puzzled how BMY could be down from biotech_researcher 06/12/20 02:44:12 PM
#930   FDA approves Opdivo monotherapy for second-line esophageal cancer—irrespective DewDiligence 06/11/20 10:38:52 AM
#929   Zeposia hits primary/secondary endpoints in UC phase-3: DewDiligence 06/02/20 11:02:06 AM
#928   BMY launches Zeposia (ozanimod) for RMS: DewDiligence 06/01/20 10:49:18 AM
#927   FDA approves Opdivo/Yervoy in 1L-NSCLC following two cycles DewDiligence 05/26/20 06:40:06 PM
#926   BMY inks oncology-drug-discovery collaboration with—(private)—Repare Therapeutic DewDiligence 05/26/20 05:19:44 PM
#925   Great company. Great products. Perennial winner Flying Albatross 05/22/20 03:18:57 PM
#924   EMA validates BMY MAA’s for bb2121 and CC-486: DewDiligence 05/22/20 09:54:22 AM
#923   BMY PR on FDA approval in NSCLC: DewDiligence 05/15/20 06:09:50 PM
#922   FDA approves Opdivo/Yervoy in 1L-NSCLC—for PD-L1>=1%—based on OS DewDiligence 05/15/20 03:21:02 PM
#921   BMY-CELG’s CVR* -28% on bb2121 RTF letter. DewDiligence 05/13/20 11:04:29 AM
#920   BMY’s ASCO lineup: DewDiligence 05/11/20 12:30:24 PM
#919   BMY pays BLUE $200M lump-sum in lieu of DewDiligence 05/11/20 11:36:56 AM
PostSubject
Consent Preferences